...
首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Utility of transfer factor to detect different bronchodilator responses in patients with chronic obstructive pulmonary disease.
【24h】

Utility of transfer factor to detect different bronchodilator responses in patients with chronic obstructive pulmonary disease.

机译:转移因子在慢性阻塞性肺疾病患者中检测不同支气管扩张剂反应的效用。

获取原文
获取原文并翻译 | 示例
           

摘要

Previous studies have described that there are different types of disease in patients with established chronic obstructive pulmonary disease (COPD) with different clinical course and functional responses. The aim of this study was to evaluate if the presence of low transfer factor (LTF) values can predict the effectiveness of bronchodilator therapy, and to assess whether this group has different risk factors that may be related with the responses. Eighty patients with COPD were evaluated on three occasions. Initial assessment included a standard respiratory questionnaire, blood analysis, skin prick test and baseline lung function, all performed on the first visit. Bronchodilator response was evaluated after low (0.2 mg) and high (1 mg) doses of salbutamol, and after 2 weeks of oral prednisone. In patients with normal TLCO/VA % (NTF), a higher proportion of subjects with previous history of atopy was the only statistically significant difference compared to those with LTF (odds ratio 4.33; 95% confidence interval 1.06-25.15). Although the mean response in forced expiratory volume in 1 s (FEV1) to treatment was analogous in both groups, when bronchodilation was expressed as percent of predicted, there was a clear trend to a lower response in patients with LTF (0.2 mg salbutamol: 6.99 +/- 5.64 vs. 8.94 +/- 6. 61, p = 0.15; 1 mg salbutamol: 10.18 +/- 6.37 vs. 13.45 +/- 7.90, p < 0.05; oral prednisone: 5.51 +/- 6.94 vs. 8.74 +/- 10.81, p = 0.06). The percentage of patients who had >12% improvement from that predicted in FEV1 was also lower in this group (42 vs. 72%; p < 0. 05). Moreover, TLCO/VA% was significantly lower in those subjects with a negative bronchodilator trial with salbutamol (68 +/- 25 vs. 81 +/- 26; p < 0.05) and prednisone (69 +/- 26 vs. 90 +/- 22; p < 0. 01). In patients with LTF and NTF, airway responsiveness was only significantly related with basal airflow limitation (LTF, r = 0.44; NTF, r = 0.38). All other interaction terms were not statistically significant. These results indicate that in patiens with similar serverity of COPD, the presence of LTF indicates a decreased probability of a positive bronchodilator response, probably reflecting different pathological lesions. We suggest that transfer factor should be taken into consideration when bronchial response is evaluated in large clinical trials.
机译:先前的研究已经描述,已建立的慢性阻塞性肺疾病(COPD)患者的疾病类型不同,其临床过程和功能反应也不同。这项研究的目的是评估低转移因子(LTF)值的存在是否可以预测支气管扩张剂治疗的有效性,并评估该组是否具有可能与反应相关的不同危险因素。对80例COPD患者进行了3次评估。初步评估包括标准呼吸道问卷,血液分析,皮肤点刺试验和基线肺功能,所有这些均在首次就诊时进行。在低剂量(0.2 mg)和高剂量(1 mg)的沙丁胺醇以及口服泼尼松2周后评估支气管扩张剂的反应。在TLCO / VA%(NTF)正常的患者中,具有特应性病史的受试者比例较高,这是与LTF相比的唯一统计学上显着差异(优势比4.33; 95%置信区间1.06-25.15)。尽管两组的平均呼气量在1 s(FEV1)中对治疗的平均反应相似,但当支气管扩张表示为预期百分比时,LTF患者明显有降低应答的趋势(0.2 mg沙丁胺醇:6.99) +/- 5.64 vs. 8.94 +/- 6. 61,p = 0.15; 1毫克沙丁胺醇:10.18 +/- 6.37 vs. 13.45 +/- 7.90,p <0.05;口服泼尼松:5.51 +/- 6.94 vs. 8.74 +/- 10.81,p = 0.06)。与FEV1预测的相比改善了> 12%的患者百分比在该组中也较低(42比72%; p <0. 05)。此外,在沙丁胺醇(68 +/- 25 vs. 81 +/- 26; p <0.05)和泼尼松(69 +/- 26 vs. 90 + /)的支气管扩张剂试验阴性的受试者中,TLCO / VA%显着降低。 -22; p <0. 01)。在患有LTF和NTF的患者中,气道反应性仅与基础气流受限显着相关(LTF,r = 0.44; NTF,r = 0.38)。所有其他互动条件在统计上都不显着。这些结果表明,在患有与COPD相似的患者中,LTF的存在表明支气管扩张剂阳性反应的可能性降低,可能反映了不同的病理病变。我们建议在大型临床试验中评估支气管反应时应考虑转移因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号